Application of antalzyme and gene recombinate antalzyme 134 pure products in the preparation of birds and livestock diseases treating medicine

A technology of lysozyme and human lysozyme, which is applied in the direction of antibacterial drugs, pharmaceutical formulations, climate change adaptation, etc., can solve problems such as the application of lysozyme that has not been seen, and achieve the effect of reducing dosage, reducing bactericidal concentration, and reducing residual amount

Inactive Publication Date: 2004-11-10
长春奇龙生物技术研究所
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no application of lysozyme in poultry pharmaceuticals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0045] Experimental Example 1: Recombinant Lysozyme 134 Anti-infection Experiment of Protecting Duroc Pigs

[0046] 1. Materials

[0047] 1. Strain: Salmonella, 2. Animal: Duroc pig

[0048] 2. Method

[0049] recombinant lysozyme 134 Recombinant lysozyme used in anti-infection experiments to protect Duroc pigs 134 The Duroc pigs were fed by gavage, and the normal feed was used as the control group. Will 1×10 9 The Salmonella in the logarithmic growth phase were inoculated into the protection group and the control group Duroc pigs respectively. Observe the results and calculate the protective power. Immune protection rate%=[(survival rate of experimental group-survival rate of control group) / death rate of control group]×100%

[0050] 3. Results

[0051] recombinant lysozyme 134 The results of the anti-infection protection experiment for the protection of Duroc pigs showed that after infection of Duroc pigs with Salmonella, the recombinant lysozyme 134 The protection...

experiment example 2

[0052] Experimental Example 2: Recombinant Lysozyme 134 Synergistic antibacterial effect with antibiotics

[0053] 1. Materials

[0054] 1. Strains: More than 400 clinical isolates were provided by Chengdu Antibiotic Industry Research Institute.

[0055] 2. Buffer pH7.2 10mM Tris-Cl buffer

[0056] 3. LB medium

[0057] 4. Clarithromycin, Roxithromycin

[0058] 2. Method

[0059] recombinant lysozyme 134 Combined with clarithromycin and roxithromycin respectively (1:1),

[0060] Method 1 (test tube method)

[0061] Staphylococcus aureus (or Escherichia coli) was made 10 with pH7.2 10mM Tris-Cl buffer solution 7 -10 8Bacterial solutions with a concentration of about CFU / mL were added to different 2mL test tubes, and different doses of human lysozyme (100 μg-1 mg) were added to different test tubes at 37°C overnight, and 20 μL of each tube was diluted with a 10-fold dilution method. Add 100 μL of 10% SDS (final concentration 0.5%) to each tube, shake well, take 100 μL ...

experiment example 3

[0066] Experimental Example 3: Recombinant Lysozyme 134 Bactericidal experiment in vivo (1)

[0067] 1. Materials

[0068] 1. Strains: Escherichia coli 2. Animals: BALB / c mice

[0069] 2. Method

[0070] Escherichia coli infection of BALB / c mice experiments will 10 5 ~10 9 Escherichia coli in the logarithmic growth phase of CFU (colony forming units) were inoculated intraperitoneally into 6-week-old BALB / c mice, and the results were observed to calculate the mortality rate. recombinant lysozyme 134 Identification of protective activity will be 1 x 10 9 Escherichia coli in logarithmic growth phase was inoculated intraperitoneally in 6-week-old BALB / c mice as infection control, recombinant lysozyme 134 The protection group was injected with different doses of recombinant lysozyme while inoculating the bacteria 134 , observe the results for 7 days, and calculate the protective power, the protection rate%=[(survival rate of the experimental group-survival rate of the contr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of lysozyme and restructured lysozyme 134 pure product or stock solution in preparing pharmaceutical preparations for the prevention and treatment for birds including chickens, ducks, geese, quails and livestock including pigs, sheep, cows, horses, donkeys, rabbits and honey bees. Wherein the restructured lysozyme 134 pure product or the combination of stock solution and antibiotics are employed to treat the diseases caused by viruses, Staphylococcus aureus, streptococcus, bacillus coli, salmonella, mycoplasma and Chlamydia.

Description

Technical field: [0001] The invention relates to a lysozyme and a recombinant lysozyme 134 Application of pure product or stock solution in poultry pharmaceuticals, especially involving a kind of lysozyme and recombinant lysozyme 134 The pure product or stock solution is used for the prevention and treatment of diseases of poultry including chicken, duck, goose, quail, livestock including pig, sheep, cattle, horse, donkey, rabbit and bee. Background technique: [0002] In recent years, due to the widespread use of antibacterial drugs, bacterial drug resistance has been continuously strengthened, and many bacteria have developed from single-drug resistance to multi-drug resistance. Adding antibacterial drugs to feed is actually equal to continuous low-dose medication. Long-term exposure of animal organisms to drugs has resulted in an increasing number of drug-resistant bacteria and increasing drug resistance. Antimicrobial drug residues in animal food also make people cont...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61P31/04
CPCY02A40/70
Inventor 张华安米安献禄
Owner 长春奇龙生物技术研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap